DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma) Pirtobrutinib Found Safe And Effective In cBTKi Pre‑Treated MCL Nov 03, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Is Well-Tolerated And Effective In Patients With R/R LBCL Oct 05, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Epcoritamab Shows Lasting Remissions in R/R LBCL Patients Oct 04, 2023
Lymphoma,MCL (Mantle Cell Lymphoma) MRD-driven Ibrutinib Discontinuation Shows Prolonged Undetectable MRD Sep 15, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),Lymphoma,MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Liso-cel Proves Safe And Effective For R/R LBCL Patients Aug 30, 2023
DLBCL (Diffuse Large B Cell Lymphoma),FL (Follicular Lymphoma),MCL (Mantle Cell Lymphoma),MZL (Marginal Zone Lymphoma) Subcutaneous Epcoritamab Achieved Complete Remissions In R/R LBCL Aug 24, 2023
Lymphoma,MCL (Mantle Cell Lymphoma) Impact of Rituximab Maintenance on Young Pts With MCL Aug 21, 2023